German

Generated Narrative: ConceptMap mii-cm-onko-atc-transitions-2021

Mapping from MII VS Onkologie Systemische Therapie Substanzen ATC 2020 to MII VS Onkologie Systemische Therapie Substanzen ATC 2021


Mapping from http://fhir.de/CodeSystem/bfarm/atc (Atc) to http://fhir.de/CodeSystem/bfarm/atc (Atc)

Source CodeRelationshipTarget CodeComment
L01XE01 (Imatinib)is equivalent toL01EA01 (Imatinib)Reklassifizierung zu BCR-ABL Tyrosinkinase-Inhibitoren
L01XE06 (Dasatinib)is equivalent toL01EA02 (Dasatinib)
L01XE08 (Nilotinib)is equivalent toL01EA03 (Nilotinib)
L01XE14 (Bosutinib)is equivalent toL01EA04 (Bosutinib)
L01XE24 (Ponatinib)is equivalent toL01EA05 (Ponatinib)
L01XE02 (Gefitinib)is equivalent toL01EB01 (Gefitinib)Reklassifizierung zu EGFR Tyrosinkinase-Inhibitoren
L01XE03 (Erlotinib)is equivalent toL01EB02 (Erlotinib)
L01XE13 (Afatinib)is equivalent toL01EB03 (Afatinib)
L01XE35 (Osimertinib)is equivalent toL01EB04 (Osimertinib)
L01XE15 (Vemurafenib)is equivalent toL01EC01 (Vemurafenib)Reklassifizierung zu BRAF-Inhibitoren
L01XE23 (Dabrafenib)is equivalent toL01EC02 (Dabrafenib)
L01XE46 (Encorafenib)is equivalent toL01EC03 (Encorafenib)
L01XE16 (Crizotinib)is equivalent toL01ED01 (Crizotinib)Reklassifizierung zu ALK-Inhibitoren
L01XE28 (Ceritinib)is equivalent toL01ED02 (Ceritinib)
L01XE36 (Alectinib)is equivalent toL01ED03 (Alectinib)
L01XE43 (Brigatinib)is equivalent toL01ED04 (Brigatinib)
L01XE44 (Lorlatinib)is equivalent toL01ED05 (Lorlatinib)
L01XE25 (Trametinib)is equivalent toL01EE01 (Trametinib)Reklassifizierung zu MEK-Inhibitoren
L01XE38 (Cobimetinib)is equivalent toL01EE02 (Cobimetinib)
L01XE41 (Binimetinib)is equivalent toL01EE03 (Binimetinib)
L01XE33 (Palbociclib)is equivalent toL01EF01 (Palbociclib)Reklassifizierung zu CDK4/6-Inhibitoren
L01XE42 (Ribociclib)is equivalent toL01EF02 (Ribociclib)
L01XE50 (Abemaciclib)is equivalent toL01EF03 (Abemaciclib)
L01XE09 (Temsirolimus)is equivalent toL01EG01 (Temsirolimus)Reklassifizierung zu mTOR-Inhibitoren
L01XE10 (Everolimus)is equivalent toL01EG02 (Everolimus)
L01XE07 (Lapatinib)is equivalent toL01EH01 (Lapatinib)Reklassifizierung zu HER2-Inhibitoren
L01XE45 (Neratinib)is equivalent toL01EH02 (Neratinib)
L01XE18 (Ruxolitinib)is equivalent toL01EJ01 (Ruxolitinib)Reklassifizierung zu JAK-Inhibitoren
L01XE17 (Axitinib)is equivalent toL01EK01 (Axitinib)Reklassifizierung zu VEGFR-Inhibitoren
L01XE34 (Tivozanib)is equivalent toL01EK03 (Tivozanib)
L01XE27 (Ibrutinib)is equivalent toL01EL01 (Ibrutinib)Reklassifizierung zu BTK-Inhibitoren
L01XE51 (Acalabrutinib)is equivalent toL01EL02 (Acalabrutinib)
L01XX47 (Idelalisib)is equivalent toL01EM01 (Idelalisib)Reklassifizierung zu PI3K-Inhibitoren
L01XX61 (Copanlisib)is equivalent toL01EM02 (Copanlisib)
L01XE04 (Sunitinib)is equivalent toL01EX01 (Sunitinib)Reklassifizierung zu andere Proteinkinase-Inhibitoren
L01XE05 (Sorafenib)is equivalent toL01EX02 (Sorafenib)
L01XE12 (Vandetanib)is equivalent toL01EX04 (Vandetanib)
L01XE21 (Regorafenib)is equivalent toL01EX05 (Regorafenib)
L01XE26 (Cabozantinib)is equivalent toL01EX07 (Cabozantinib)
L01XE29 (Lenvatinib)is equivalent toL01EX08 (Lenvatinib)
L01XE31 (Nintedanib)is equivalent toL01EX09 (Nintedanib)
L01XE39 (Midostaurin)is equivalent toL01EX10 (Midostaurin)
L01XE52 (Quizartinib)is equivalent toL01EX11 (Quizartinib)
L01XE53 (Larotrectinib)is equivalent toL01EX12 (Larotrectinib)
L01XE54 (Gilteritinib)is equivalent toL01EX13 (Gilteritinib)
L01XX14 (Tretinoin)is equivalent toL01XF01 (Tretinoin)Reklassifizierung zu Retinoide
L01XX22 (Alitretinoin)is equivalent toL01XF02 (Alitretinoin)
L01XX25 (Bexaroten)is equivalent toL01XF03 (Bexaroten)
L01XX32 (Bortezomib)is equivalent toL01XG01 (Bortezomib)Reklassifizierung zu Proteasom-Inhibitoren
L01XX45 (Carfilzomib)is equivalent toL01XG02 (Carfilzomib)
L01XX50 (Ixazomib)is equivalent toL01XG03 (Ixazomib)
L01XX38 (Vorinostat)is equivalent toL01XH01 (Vorinostat)Reklassifizierung zu Histon-Deacetylase-Inhibitoren
L01XX39 (Romidepsin)is equivalent toL01XH02 (Romidepsin)
L01XX42 (Panobinostat)is equivalent toL01XH03 (Panobinostat)
L01XX49 (Belinostat)is equivalent toL01XH04 (Belinostat)
L01XX43 (Vismodegib)is equivalent toL01XJ01 (Vismodegib)Reklassifizierung zu Hedgehog-Signalweg-Inhibitoren
L01XX63 (Glasdegib)is equivalent toL01XJ03 (Glasdegib)
L01XX46 (Olaparib)is equivalent toL01XK01 (Olaparib)Reklassifizierung zu PARP-Inhibitoren
L01XX54 (Niraparib)is equivalent toL01XK02 (Niraparib)
L01XX60 (Talazoparib)is equivalent toL01XK04 (Talazoparib)
L01XX17 (Topotecan)is equivalent toL01CE01 (Topotecan)Reklassifizierung zu Topoisomerase-I-Inhibitoren
L01XX19 (Irinotecan)is equivalent toL01CE02 (Irinotecan)
 <status value="active"/> <experimental value="false"/> <date value="2024-12-12"/> <publisher value="Medizininformatik Initiative"/> <contact> <name value="Medizininformatik Initiative"/> <telecom> <system value="url"/> <value value="https://www.medizininformatik-initiative.de/"/> </telecom> </contact> <description value="Diese ConceptMap dokumentiert ausschließlich die ATC-Code-Änderungen von 2020 zu 2021. Im Jahr 2021 erfolgte eine umfassende Reorganisation der ATC-Klassifikation für onkologische Substanzen mit Umkodierung von über 60 Wirkstoffen."/> <jurisdiction> <coding> <system value="urn:iso:std:iso:3166"/> <code value="DE"/> <display value="Germany"/> </coding> </jurisdiction> <purpose value="Migration von ATC-Codes für Substanzen, die 2021 umkodiert wurden. Enthält nur geänderte Codes, keine neuen oder unveränderten Einträge."/> <sourceCanonical value="https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2020"/> <targetCanonical value="https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2021"/> <group> <source value="http://fhir.de/CodeSystem/bfarm/atc"/> <target value="http://fhir.de/CodeSystem/bfarm/atc"/> <element> <code value="L01XE01"/> <display value="Imatinib"/> <target> <code value="L01EA01"/> <display value="Imatinib"/> <equivalence value="equivalent"/> <comment value="Reklassifizierung zu BCR-ABL Tyrosinkinase-Inhibitoren"/> </target> </element> <element> <code value="L01XE06"/> <display value="Dasatinib"/> <target> <code value="L01EA02"/> <display value="Dasatinib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE08"/> <display value="Nilotinib"/> <target> <code value="L01EA03"/> <display value="Nilotinib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE14"/> <display value="Bosutinib"/> <target> <code value="L01EA04"/> <display value="Bosutinib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE24"/> <display value="Ponatinib"/> <target> <code value="L01EA05"/> <display value="Ponatinib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE02"/> <display value="Gefitinib"/> <target> <code value="L01EB01"/> <display value="Gefitinib"/> <equivalence value="equivalent"/> <comment value="Reklassifizierung zu EGFR Tyrosinkinase-Inhibitoren"/> </target> </element> <element> <code value="L01XE03"/> <display value="Erlotinib"/> <target> <code value="L01EB02"/> <display value="Erlotinib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE13"/> <display value="Afatinib"/> <target> <code value="L01EB03"/> <display value="Afatinib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE35"/> <display value="Osimertinib"/> <target> <code value="L01EB04"/> <display value="Osimertinib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE15"/> <display value="Vemurafenib"/> <target> <code value="L01EC01"/> <display value="Vemurafenib"/> <equivalence value="equivalent"/> <comment value="Reklassifizierung zu BRAF-Inhibitoren"/> </target> </element> <element> <code value="L01XE23"/> <display value="Dabrafenib"/> <target> <code value="L01EC02"/> <display value="Dabrafenib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE46"/> <display value="Encorafenib"/> <target> <code value="L01EC03"/> <display value="Encorafenib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE16"/> <display value="Crizotinib"/> <target> <code value="L01ED01"/> <display value="Crizotinib"/> <equivalence value="equivalent"/> <comment value="Reklassifizierung zu ALK-Inhibitoren"/> </target> </element> <element> <code value="L01XE28"/> <display value="Ceritinib"/> <target> <code value="L01ED02"/> <display value="Ceritinib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE36"/> <display value="Alectinib"/> <target> <code value="L01ED03"/> <display value="Alectinib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE43"/> <display value="Brigatinib"/> <target> <code value="L01ED04"/> <display value="Brigatinib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE44"/> <display value="Lorlatinib"/> <target> <code value="L01ED05"/> <display value="Lorlatinib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE25"/> <display value="Trametinib"/> <target> <code value="L01EE01"/> <display value="Trametinib"/> <equivalence value="equivalent"/> <comment value="Reklassifizierung zu MEK-Inhibitoren"/> </target> </element> <element> <code value="L01XE38"/> <display value="Cobimetinib"/> <target> <code value="L01EE02"/> <display value="Cobimetinib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE41"/> <display value="Binimetinib"/> <target> <code value="L01EE03"/> <display value="Binimetinib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE33"/> <display value="Palbociclib"/> <target> <code value="L01EF01"/> <display value="Palbociclib"/> <equivalence value="equivalent"/> <comment value="Reklassifizierung zu CDK4/6-Inhibitoren"/> </target> </element> <element> <code value="L01XE42"/> <display value="Ribociclib"/> <target> <code value="L01EF02"/> <display value="Ribociclib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE50"/> <display value="Abemaciclib"/> <target> <code value="L01EF03"/> <display value="Abemaciclib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE09"/> <display value="Temsirolimus"/> <target> <code value="L01EG01"/> <display value="Temsirolimus"/> <equivalence value="equivalent"/> <comment value="Reklassifizierung zu mTOR-Inhibitoren"/> </target> </element> <element> <code value="L01XE10"/> <display value="Everolimus"/> <target> <code value="L01EG02"/> <display value="Everolimus"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE07"/> <display value="Lapatinib"/> <target> <code value="L01EH01"/> <display value="Lapatinib"/> <equivalence value="equivalent"/> <comment value="Reklassifizierung zu HER2-Inhibitoren"/> </target> </element> <element> <code value="L01XE45"/> <display value="Neratinib"/> <target> <code value="L01EH02"/> <display value="Neratinib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE18"/> <display value="Ruxolitinib"/> <target> <code value="L01EJ01"/> <display value="Ruxolitinib"/> <equivalence value="equivalent"/> <comment value="Reklassifizierung zu JAK-Inhibitoren"/> </target> </element> <element> <code value="L01XE17"/> <display value="Axitinib"/> <target> <code value="L01EK01"/> <display value="Axitinib"/> <equivalence value="equivalent"/> <comment value="Reklassifizierung zu VEGFR-Inhibitoren"/> </target> </element> <element> <code value="L01XE34"/> <display value="Tivozanib"/> <target> <code value="L01EK03"/> <display value="Tivozanib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE27"/> <display value="Ibrutinib"/> <target> <code value="L01EL01"/> <display value="Ibrutinib"/> <equivalence value="equivalent"/> <comment value="Reklassifizierung zu BTK-Inhibitoren"/> </target> </element> <element> <code value="L01XE51"/> <display value="Acalabrutinib"/> <target> <code value="L01EL02"/> <display value="Acalabrutinib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XX47"/> <display value="Idelalisib"/> <target> <code value="L01EM01"/> <display value="Idelalisib"/> <equivalence value="equivalent"/> <comment value="Reklassifizierung zu PI3K-Inhibitoren"/> </target> </element> <element> <code value="L01XX61"/> <display value="Copanlisib"/> <target> <code value="L01EM02"/> <display value="Copanlisib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE04"/> <display value="Sunitinib"/> <target> <code value="L01EX01"/> <display value="Sunitinib"/> <equivalence value="equivalent"/> <comment value="Reklassifizierung zu andere Proteinkinase-Inhibitoren"/> </target> </element> <element> <code value="L01XE05"/> <display value="Sorafenib"/> <target> <code value="L01EX02"/> <display value="Sorafenib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE12"/> <display value="Vandetanib"/> <target> <code value="L01EX04"/> <display value="Vandetanib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE21"/> <display value="Regorafenib"/> <target> <code value="L01EX05"/> <display value="Regorafenib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE26"/> <display value="Cabozantinib"/> <target> <code value="L01EX07"/> <display value="Cabozantinib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE29"/> <display value="Lenvatinib"/> <target> <code value="L01EX08"/> <display value="Lenvatinib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE31"/> <display value="Nintedanib"/> <target> <code value="L01EX09"/> <display value="Nintedanib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE39"/> <display value="Midostaurin"/> <target> <code value="L01EX10"/> <display value="Midostaurin"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE52"/> <display value="Quizartinib"/> <target> <code value="L01EX11"/> <display value="Quizartinib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE53"/> <display value="Larotrectinib"/> <target> <code value="L01EX12"/> <display value="Larotrectinib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XE54"/> <display value="Gilteritinib"/> <target> <code value="L01EX13"/> <display value="Gilteritinib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XX14"/> <display value="Tretinoin"/> <target> <code value="L01XF01"/> <display value="Tretinoin"/> <equivalence value="equivalent"/> <comment value="Reklassifizierung zu Retinoide"/> </target> </element> <element> <code value="L01XX22"/> <display value="Alitretinoin"/> <target> <code value="L01XF02"/> <display value="Alitretinoin"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XX25"/> <display value="Bexaroten"/> <target> <code value="L01XF03"/> <display value="Bexaroten"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XX32"/> <display value="Bortezomib"/> <target> <code value="L01XG01"/> <display value="Bortezomib"/> <equivalence value="equivalent"/> <comment value="Reklassifizierung zu Proteasom-Inhibitoren"/> </target> </element> <element> <code value="L01XX45"/> <display value="Carfilzomib"/> <target> <code value="L01XG02"/> <display value="Carfilzomib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XX50"/> <display value="Ixazomib"/> <target> <code value="L01XG03"/> <display value="Ixazomib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XX38"/> <display value="Vorinostat"/> <target> <code value="L01XH01"/> <display value="Vorinostat"/> <equivalence value="equivalent"/> <comment value="Reklassifizierung zu Histon-Deacetylase-Inhibitoren"/> </target> </element> <element> <code value="L01XX39"/> <display value="Romidepsin"/> <target> <code value="L01XH02"/> <display value="Romidepsin"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XX42"/> <display value="Panobinostat"/> <target> <code value="L01XH03"/> <display value="Panobinostat"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XX49"/> <display value="Belinostat"/> <target> <code value="L01XH04"/> <display value="Belinostat"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XX43"/> <display value="Vismodegib"/> <target> <code value="L01XJ01"/> <display value="Vismodegib"/> <equivalence value="equivalent"/> <comment value="Reklassifizierung zu Hedgehog-Signalweg-Inhibitoren"/> </target> </element> <element> <code value="L01XX63"/> <display value="Glasdegib"/> <target> <code value="L01XJ03"/> <display value="Glasdegib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XX46"/> <display value="Olaparib"/> <target> <code value="L01XK01"/> <display value="Olaparib"/> <equivalence value="equivalent"/> <comment value="Reklassifizierung zu PARP-Inhibitoren"/> </target> </element> <element> <code value="L01XX54"/> <display value="Niraparib"/> <target> <code value="L01XK02"/> <display value="Niraparib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XX60"/> <display value="Talazoparib"/> <target> <code value="L01XK04"/> <display value="Talazoparib"/> <equivalence value="equivalent"/> </target> </element> <element> <code value="L01XX17"/> <display value="Topotecan"/> <target> <code value="L01CE01"/> <display value="Topotecan"/> <equivalence value="equivalent"/> <comment value="Reklassifizierung zu Topoisomerase-I-Inhibitoren"/> </target> </element> <element> <code value="L01XX19"/> <display value="Irinotecan"/> <target> <code value="L01CE02"/> <display value="Irinotecan"/> <equivalence value="equivalent"/> </target> </element> </group> </ConceptMap>